Much has changed in the 10 years since our first survey of industry researchers. Large companies are now looking to small, nimble ones for services as well as innovation.
The Scientist
Most Recent
One cancer researcher says that by focusing solely on stalling cancer growth, clinical trials are failing some potentially life-saving drugs that prevent metastasis.
Major pharmaceutical companies have agreed to a handful of recommendations aimed at increasing the transparency of clinical trials they fund.
Amgen’s incomplete report on an early major trial of epoetin misled the medical community about the anemia drug’s risks and benefits—and helped make Amgen rich.
The FDA is on board with a proposal to speed the approval of experimental pharmaceuticals that show big treatment effects early in clinical testing.
A new bill aims to increase transparency in cancer clinical trials by requiring researchers to divulge all outcomes.
The FDA and NIH dispute reports that clinical trial data is being under-reported.
What lies untapped beneath the surface of published clinical trial analyses could rock the world of independent review.
Francis Collins says pharmaceutical companies should help bridge the gap between basic science and applications with old drug compounds.
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
